Saiyong Zhu

Saiyong Zhu

Auto-generated profile, based on publicly available information

Saiyong Zhu

Life Sciences Institute, The Second Affiliated Hospital and School of Medicine, The MOE Key Laboratory of Biosystems Homeostasis and Protection and Zhejiang Provincial Key Laboratory for Cancer Molecular Cell Biology, Zhejiang University, Hangzhou, Zhejiang 310058, China

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 February 2017 in Protein & Cell
Verified
Journal Article
Open access
PDF file
XMXiaojie Ma
Xiaojie Ma
LKLinghao Kong
Linghao Kong
SZSaiyong Zhu
Saiyong Zhu
Reprogramming cell fates towards pluripotent stem cells and other cell types has revolutionized our understanding of cellular plasticity. During the last decade, transcription factors and microRNAs have become powerful reprogramming factors for modulating cell fates. Recently, many efforts are focused on reprogramming cell fates by non-viral and non-integrating chemical approaches. Small molecules not only are useful in generating desired cell types in vitro for various applications, such as disease modeling and cell-based transplantation, but also hold great promise to be further developed as drugs to stimulate patients’ endogenous cells to repair and regenerate in vivo. Here we will focus on chemical approaches for generating induced pluripotent stem cells, neurons, cardiomyocytes, hepatocytes and pancreatic β cells. Significantly, the rapid and exciting advances in cellular reprogramming by small molecules will help us to achieve the long-term goal of curing devastating diseases, injuries, cancers and aging.

3 April 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
XMXiaojie Ma
Xiaojie Ma
XCXi Chen
Xi Chen
YJYan Jin
Yan Jin
WGWenyan Ge
Wenyan Ge
WWWeiyun Wang
Weiyun Wang
SZSaiyong Zhu
Saiyong Zhu
Human pluripotent stem cells (hPSCs) have potential applications in biological studies and regenerative medicine. However, precise genome editing in hPSCs remains time-consuming and labor-intensive. Here we demonstrate that the recently identified CRISPR-Cpf1 can be used to efficiently generate knockout and knockin hPSC lines. The unique properties of CRISPR-Cpf1, including shorter crRNA length and low off-target activity, are very attractive for many applications. In particular, we develop an unbiased drug-selection-based platform feasible for high-throughput screening in hPSCs and this screening system enables us to identify small molecules VE-822 and AZD-7762 that can promote CRISPR-Cpf1-mediated precise genome editing. Significantly, the combination of CRISPR-Cpf1 and small molecules provides a simple and efficient strategy for precise genome engineering.

25 February 2022 in Science Advances
Verified
Journal Article
Open access
XMXiaojie Ma
Xiaojie Ma
YLYunkun Lu
Yunkun Lu
ZZZiyu Zhou
Ziyu Zhou
QLQin Li
Qin Li
XCXi Chen
Xi Chen
SZSaiyong Zhu
Saiyong Zhu
An unlimited source of human pancreatic β cells is in high demand. Even with recent advances in pancreatic differentiation from human pluripotent stem cells, major hurdles remain in large-scale and cost-effective production of functional β cells. Here, through chemical screening, we demonstrate that the bromodomain and extraterminal domain (BET) inhibitor I-BET151 can robustly promote the expansion of PDX1 + NKX6.1 + pancreatic progenitors (PPs). These expandable PPs (ePPs) maintain pancreatic progenitor cell status in the long term and can efficiently differentiate into functional pancreatic β (ePP-β) cells. Notably, transplantation of ePP-β cells rapidly ameliorated diabetes in mice, suggesting strong potential for cell replacement therapy. Mechanistically, I-BET151 activates Notch signaling and promotes the expression of key PP-associated genes, underscoring the importance of epigenetic and transcriptional modulations for lineage-specific progenitor self-renewal. In summary, our studies achieve the long-term goal of robust expansion of PPs and represent a substantial step toward unlimited supplies of functional β cells for biomedical research and regenerative medicine.

12 January 2024 in Science Advances
Verified
Journal Article
Open access
ZHZhensheng Hu
Zhensheng Hu
YLYunkun Lu
Yunkun Lu
JCJie Cao
Jie Cao
LLLianyu Lin
Lianyu Lin
XCXi Chen
Xi Chen
SZSaiyong Zhu
Saiyong Zhu
Cell fate transition involves dynamic changes of gene regulatory network and chromatin landscape, requiring multiple levels of regulation, yet the cross-talk between epitranscriptomic modification and chromatin signaling remains largely unknown. Here, we uncover that suppression of N -acetyltransferase 10 (NAT10), the writer for mRNA N 4 -acetylcytidine (ac 4 C) modification, can notably affect human embryonic stem cell (hESC) lineage differentiation and pluripotent reprogramming. With integrative analysis, we identify that NAT10-mediated ac 4 C modification regulates the protein levels of a subset of its targets, which are strongly enriched for fate-instructive chromatin regulators, and among them, histone chaperone ANP32B is experimentally verified and functionally relevant. Furthermore, NAT10-ac 4 C-ANP32B axis can modulate the chromatin landscape of their downstream genes (e.g., key regulators of Wnt and TGFβ pathways). Collectively, we show that NAT10 is an essential regulator of cellular plasticity, and its catalyzed mRNA cytidine acetylation represents a critical layer of epitranscriptomic modulation and uncover a previously unrecognized, direct cross-talk between epitranscriptomic modification and chromatin signaling during cell fate transitions.

7 August 2023 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
XCXi Chen
Xi Chen
YLYunkun Lu
Yunkun Lu
LWLeyun Wang
Leyun Wang
XMXiaojie Ma
Xiaojie Ma
JPJiaqi Pu
Jiaqi Pu
SZSaiyong Zhu
Saiyong Zhu

28 April 2021 in The EMBO Journal
Verified
Journal Article
Closed access
PDF file
WWWeiyun Wang
Weiyun Wang
SRShaofang Ren
Shaofang Ren
YLYunkun Lu
Yunkun Lu
XCXi Chen
Xi Chen
JQJuanjuan Qu
Juanjuan Qu
SZSaiyong Zhu
Saiyong Zhu